A public clinical stage company focused on immune modulation for the treatment of cancer and other specific diseases. The Company’s corporate website is www.therapeuticsolutionsint.com. New products can be viewed on www.projuvenol.com and ordered at www.youcanordernow.com. Recent News:
Therapeutic Solutions files new Patent on Targeting the Tumor Microenvironment through Nutraceutical Based Immunoadjuvants http://www.marketwired.com/press-release/therapeutic-solutions-files-new-patent-on-targeting-tumor-microenvironment-through-nutraceutical-otc-pink-tsoi-2215015.htm Therapeutic Solutions International Announces Appointment of Dr. Thomas E. Ichim to its Subsidiary Emvolio, Inc. http://www.marketwired.com/press-release/therapeutic-solutions-international-announces-appointment-dr-thomas-e-ichim-its-subsidiary-otc-pink-tsoi-2213091.htm
Therapeutic Solutions International's Subsidiary, Emvolio, Inc., Files Investigational New Drug Application for StemVacs Cancer Immunotherapy http://www.marketwired.com/press-release/therapeutic-solutions-international-announces-filing-new-immunotherapy-patent-exclusive-otc-pink-tsoi-2208787.htm Therapeutic Solutions Receives Allowance on Patent Claim from the US Patent Office Covering ProJuvenol® Active Ingredient Pterostilbene in Cancer Immunotherapies
Therapeutic Solutions International Reports Augmentation of Cancer Immunotherapy Using Pterostilbene http://www.marketwired.com/press-release/therapeutic-solutions-international-reports-augmentation-cancer-immunotherapy-using-otc-pink-tsoi-2141234.htm
Subsidiaries: Omnibiome , Inc .
Share Structure - 46M Float
|Shares Outstanding ||682,751,000 ||a/o July 31 , 2016 |
|Float ||46,312,028 ||a/o July 31 , 2016 |
|Authorized Shares ||995,000,000 ||a/o July 31 , 2016 |
(As of July 20 , 2016 , OmniBiome , Inc is majority-owned by TSI)
Emvolio , Inc . (As of April 10 , 2017 Emvolio , Inc is majority-owned by TSI) http://emvolio.com/
Officers and Directors:
Timothy G. Dixon – President, CEO, & Chairman
Mr. Dixon currently serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc. Mr. Dixon also serves as President and Chairman of OmniBiome, Inc. and President and Chairman of Emvolio, Inc. Mr. Dixon previously served as the President of TMD Courses, Inc. from 2006 to 2012 and; as the President of Splint Decisions Inc. from 2010 to 2011.
Mr. Dixon has attended hundreds of hours of continuing medical/dental education throughout the years and has produced many educational DVD’s used by dental professionals worldwide on the subject of parafunctional control, migraine prevention, therapeutic Botox injections, migraine pathophysiology, dental sleep medicine, and other therapeutic protocols. Mr. Dixon also has extensive experience in dealing with corporate compliance matters with the U.S. Food and Drug Administration, (FDA) as well as many international regulatory bodies.
Gerry B. Berg – Vice President, CFO, Director?
Gerry B. Berg has served as our Vice-President and Chief Financial Officer since April 20, 2011. Mr. Berg also serves as Chief Financial Officer and Director of OmniBiome, Inc. and Chief Financial Officer and Director of Emvolio, Inc. Mr. Berg became a director of the Company on August 24, 2012. Mr. Berg has over 30 years of senior management experience working with private and public companies. From May 2010 to March 2011, Mr. Berg served as President and Chairman of the Board of Directors of Friendly Auto Dealers, Inc., and also served in a consulting capacity from March 2009 to May 2010.
Mr. Berg holds a Bachelors of Science in Accounting from Walsh College where he graduated Cum Laude. Mr. Berg became a Certified Public Accountant in the State of Michigan in 1979 and in the State of California in 1984. Mr. Berg does not currently practice as a Certified Public Accountant.
Thomas E. Ichim, Ph.D – Director
Dr. Ichim was appointed to the Board of Directors on January 22, 2016. Dr. Ichim also serves as Chief Executive Officer of Emvolio, Inc. Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Batu Biologics, Inc., Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. To date he has published 99 peer-reviewed articles and is co-editor of the textbooks “RNA Interference: From Bench to Clinical Translation” and “Immuno-Oncology Text Book.”
Dr. Ichim is an ad-hoc editor and sits on several editorial boards. Dr Ichim is inventor on over 50 patents and patent applications. Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Dr. Ichim has extensive experience in product development, regulatory filings, and business development.
Dr. Ichim has a BSc in Biology from the University of Waterloo, Waterloo, Ontario, Canada, a MSc in Microbiology and Immunology a University of Western Ontario, London, Ontario, Canada and a Ph.D in Immunology from the University of Sciences Arts and Technology, Olveston Monserrat.
Hong Ma, MD, Ph.D., M.B.A. – Chief Scientific Officer
Dr. Ma has an extensive history in academic and translational research. Subsequent to completing her medical degree, she performed basic research in the area of molecular biology of endothelial-associated pathways in her doctorate and postdoctoral studies. She has been critical in establishing numerous ventures and collaborations in the area of biosciences. Dr. Ma has over 20 peer-reviewed publications and has worked with prestigious institutions in the USA, China, and Japan. She received her M.D. from Dalian Medical University, her Ph.D in Cardiovascular Pharmacology at Asahikawa Medical College, and has also earned her MBA at the Rady School of Management at the University of California San Diego.
CEO email address:
Therapeutic Solutions International, Inc. 4093 Oceanside Blvd Suite B
Oceanside CA 92056